Amgen
Amgen yesterday sued HHS and HRSA in defense of its conditions on 340B pricing when hospitals use contract pharmacies.

Amgen Sues HHS in Defense of the Company’s 340B Contract Pharmacy Restrictions

Biopharmaceutical manufacturer Amgen yesterday became the 10th drug manufacturer to sue the federal government over the government’s position that the 340B statute requires drug companies to provide 340B-priced drugs to multiple contract pharmacies without conditions.

California-based Amgen filed suit Dec. 19 in federal district court in Washington. It joins AstraZeneca, Boehringer Ingelheim, Lilly, Merck, Novartis, Novo Nordisk, Sanofi, UCB, and United Therapeutics in suing in defense of policies that generally limit covered entities to one contract pharmacy if the entities lack an in-house pharmacy. Several of the companies let entities use multiple contract pharmacies in exchange for the entities’ related 340B drug claims data.

Biopharmaceutical manufacturer Amgen yesterday became the 10th drug manufacturer to sue the federal government over the government’s position that the 340B statute requires drug companies to provide 340B-priced drugs to multiple contract pharmacies without conditions.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Attend Our Upcoming Webinar

×


Learn More

Sign up for our free news summaries and alerts